imatinib mesylate — CareFirst (Caremark)
Myelodysplastic Syndromes/Myeloproliferative Diseases (MDS/MPD)
Initial criteria
- Disease associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months